Literature DB >> 16026325

Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.

Oleg V Evgenov1, Lucas Liaudet.   

Abstract

Reactive oxygen and nitrogen species, particularly peroxynitrite, are potent inducers of tissue damage during systemic inflammatory response and circulatory shock. Recent evidence indicates that the toxicity of these species largely depends on their ability to trigger activation of the nuclear enzyme poly(adenosine 5'-diphosphate ribose) polymerase-1 (PARP-1). Following excessive activation, PARP-1 depletes the intracellular stores of its substrate, nicotinamide adenine dinucleotide, thus slowing glycolysis, generation of high energy phosphates, and mitochondrial electron transport. Consequently, the severe metabolic crisis induced by PARP-1 activation results in acute cell dysfunction and necrotic cell death. In addition, activation of PARP-1 plays an important role in the upregulation of inflammatory cascades via a functional association with mitogen-activated protein kinases and several transcription factors, such as nuclear factor kappa B, resulting in augmented expression of pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes. In severe sepsis and hemorrhage, PARP-1 activation has emerged as one of the central mechanisms of systemic inflammation, endothelial dysfunction, peripheral vascular failure, and reduction of cardiac contractility. Innovative therapeutic strategies based on the pharmacological inhibition of PARP-1 catalytic activity might provide benefits by preventing tissue injury, organ dysfunction, and lethality associated with these conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026325     DOI: 10.2174/1570161054368580

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  12 in total

Review 1.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

2.  Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.

Authors:  Partha Mukhopadhyay; Béla Horváth; Malek Kechrid; Galin Tanchian; Mohanraj Rajesh; Amarjit S Naura; A Hamid Boulares; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-08-17       Impact factor: 7.376

Review 3.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

4.  Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo.

Authors:  Sandra Levrand; Christine Vannay-Bouchiche; Benoît Pesse; Pal Pacher; François Feihl; Bernard Waeber; Lucas Liaudet
Journal:  Free Radic Biol Med       Date:  2006-06-07       Impact factor: 7.376

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 7.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 8.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

9.  New mechanisms for transcriptional repression of ENaC And iNOS.

Authors:  Bruce C Kone; Zhang Wenzhang; Yu Zhiyuan
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

Review 10.  PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis.

Authors:  Weronika Wasyluk; Agnieszka Zwolak
Journal:  J Inflamm Res       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.